Exonate Ltd, a developer of small molecule therapeutics to treat retinal vascular diseases, has named Rafiq Hasan as non-executive director to its board. The appointment comes as the company develops its lead candidate for diabetic eye disease, EXN407, toward Phase 2b clinical trials. Dr Hasan has years of expertise in ophthalmology, particularly diabetic eye disease. He is currently chief executive officer of Complement Therapeutics and was previously global head of ophthalmology at Bayer AG.
Exonate announced the appointment on 28 May 2024.
Copyright 2024 Evernow Publishing Ltd
